Evolving Strategies in the Treatment of Hematologic Malignancies

Meeting Overview
We are pleased to invite you to our satellite symposium, titled Evolving Strategies in the Treatment of Hematologic Malignancies, to be held on 9 June 2011 at the 16th Congress of the European Hematology Association in London, United Kingdom.

Date and Location
9 June 2011 ExCel London One Western Gateway Royal Victoria Dock, London E16 1XL United Kingdom Hall S2

Target Audience
This educational activity is specifically designed for hematologists, oncologists, and other healthcare professionals involved and/or interested in the management of patients with hematologic malignancies.

Learning Objectives

Upon completion of this educational activity, attendees should be able to:

Evaluate the efficacy and safety of currently available treatment options for chronic myelogenous leukemia and explain how to integrate optimal treatments in clinical practice
Discuss current and emerging therapeutic options for the front-line treatment of multiple myeloma with a focus on novel drug combinations that may enhance clinical outcomes to therapy
Analyze clinical trial data regarding the use of novel therapies in the management of relapsed or refractory multiple myeloma
Assess current standards of care for paroxysmal nocturnal hemoglobinuria and discuss ways to incorporate emerging treatment strategies into clinical practice

Chair
John Goldman, DM
Imperial College School of Medicine
London, United Kingdom

Faculty
Giuseppe Saglio, MD
University of Turin
Turin, Italy

Andrzej Jakubowiak, MD, PhD
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan, United States

Thierry Facon, MD
University Hospital Lille
Lille, France

Richard Kelly, MD
St James University Hospital
Leeds, United Kingdom

16.15		Welcome and introduction
16.20		Clinical opinion poll
16.25		How do we define "CURE" of CML in 2011? John Goldman, DM
16.40		Clinical opinion poll
16.45		Lymphocytosis following first-line treatment for CML Giuseppe Saglio, MD
17.00		Clinical opinion poll
17.05		Optimizing responses in front-line multiple myeloma Andrzej Jakubowiak, MD, PhD
17.20		Clinical opinion poll
17.25		Multiple myeloma: Emerging options in the relapse setting Thierry Facon, MD
17.40		Clinical opinion poll
17.45		Paroxysmal nocturnal hemoglobinuria: Evolving strategies and approaches Richard Kelly, MD
18.00		Ask the experts and concluding remarks All Faculty
18.15		Adjourn

Downloadable Slides
How do we define "CURE" of CML in 2011? John Goldman, DM Lymphocytosis following first-line treatment for CML Giuseppe Saglio, MD Optimizing responses in front-line multiple myeloma Andrzej Jakubowiak, MD, PhD Multiple myeloma: Emerging options in the relapse setting Thierry Facon, MD Paroxysmal nocturnal hemoglobinuria: Evolving strategies and approaches Richard Kelly, MD

Printed Materials

Continuing Professional Development
This activity has been approved for 2 External credits by the Federation of the Royal College of Physicians (UK). Delegates are reminded that a maximum of six External CPD points may be counted for educational activity on any one day. RCP Activity Code #: 64457.

Support
Support for this activity has been provided by Alexion, Bristol-Myers Squibb, and Onyx Pharmaceuticals.

Organizer
This meeting is a prIME Oncology activity.